Peer-reviewed veterinary case report
New anthrax toxin treatment targets dog mammary tumor cells
By da Fonseca, Ivone Izabel Mackowiak et al.·Published in Veterinary research communications·2024·Department of Pathology, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study.
- Species:
- dog
Plain-English summary
A study found that a reengineered anthrax toxin could effectively target and kill certain types of mammary tumors in female dogs without harming normal mammary cells. Researchers tested this treatment on five different canine mammary cell lines, including both cancerous and non-cancerous types. They discovered that two cancerous cell lines showed a significant decrease in cell viability after treatment, while the non-cancerous cells remained unaffected. This suggests that this new therapy could be a promising option for treating mammary tumors in dogs while protecting healthy tissue.
People also search for: dog mammary tumor treatment · anthrax toxin for dog cancer · canine adenocarcinoma therapy
Abstract
Mammary tumors are the most frequent type of neoplasms in intact female dogs. New therapies that target neoplastic cells without affecting normal cells are highly sought. The Bacillus anthracis toxin has been reengineered to target tumor cells that express urokinase plasminogen activators and metalloproteinases. In previous studies carried out in our laboratory, the reengineered anthrax toxin had inhibitory effects on canine oral mucosal melanoma and canine osteosarcoma cells. In this study, five canine neoplastic epithelial cell lines (four adenocarcinomas and one adenoma) and one non-neoplastic canine mammary epithelial cell line were treated with different concentrations of reengineered anthrax toxin components. Cell viability was quantified using an MTT assay and half-maximal inhibitory concentration (IC) values. Cell lines were considered sensitive when the ICwas lower than 5000 ng/ml. One canine mammary adenocarcinoma cell line and one mammary adenoma cell line showed significantly decreased viability after treatment, whereas the non-neoplastic cell line was resistant. We conclude that the reengineered anthrax toxin may be considered a targeted therapy for canine mammary neoplasms while preserving normal canine mammary epithelial cells.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38805149/